Solu-Cortef
End Stage Liver DIsease
Elizabeth C. VernaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the End Stage Liver DIsease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Giapreza University of California, Los Angeles | Phase 4 | BB |
Noradrenaline University of California, Los Angeles | Phase 4 | BB |
Benadryl Elizabeth C. Verna | Phase 1 | CC |
Siplizumab Elizabeth C. Verna | Phase 1 | C |
LACTULOSE Bogomolets National Medical University | N/A | D |
Rifaximin Bogomolets National Medical University | N/A | D |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →